×
Barnes & Noble Education (BNED) shares advanced roughly 15.1% over the trailing 30 days, rebounding from a mid-September pullback that carried the stock toward the low $10 range. A declared quarterly cash dividend and a milestone balance-sheet update were among the primary catalysts behind the move.
RH shares rose roughly 10.2% over the last 30 days, rebounding from a mid-October low near $111 to about $137 as of late October 2026. The recovery was punctuated by a 9.5% single-session surge on October 22, as investor attention shifted to the RH Estates collection, new gallery openings, and international expansion.
Consolidated revenue rose 43.1% year over year to an all-time high of MXN 4,832 million, driven by Tupperware's first full-quarter contribution. Group EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed 39.6% to MXN 1,008 million, while net income increased 24.2% in the quarter.
MarineMax is set to report fiscal fourth quarter 2026 results, covering the quarter ended September 30, 2026, alongside its full-year fiscal 2026 figures. Wall Street consensus points to roughly breakeven earnings per share (EPS) near $0.04 and revenue of about $541 million, compared with a $0.04 per-share loss and $552.2 million in revenue in the prior-year period.
Net sales rose 5.1% year over year to $3.91 billion, topping analyst expectations of roughly $3.82 billion. Diluted earnings per share (EPS) came in at $0.43, beating consensus estimates of about $0.41 but down from $0.49 a year earlier.
GME is down -3.73% in regular trading, near $25.31 versus the prior session's close of $26.29. The decline marks a pullback after seven straight weekly gains driven by CEO Ryan Cohen's insider buying spree.
Winmark reported third-quarter 2026 revenue of $27.89 million , up about 23% from $22.63 million a year earlier and well above the roughly $23.99 million consensus estimate. Diluted earnings per share (EPS) came in at $3.21 , a narrow $0.02 miss versus the $3.23 analyst consensus, while basic EPS reached $3.29.
WINA is trading down -4.88% in the regular session, falling from a previous close of $305.10 to about $290.22. The decline marks a pullback after a post-earnings surge — the stock jumped +5.5% following its Q3 report on Oct. 14 and rallied toward $328 before fading.
BBW is down -4.11% during regular market hours, trading near $23.55 versus a $24.56 prior-session close, extending its slide toward 52-week lows. No single company-specific headline drove the move; selling reflects lingering pressure after late-August Q2 results, when management cut FY2026 revenue and pre-tax income guidance.
ULTA shares advanced roughly 8% over the last 30 days, from about $549 in mid-September to around $592 in mid-October. The move followed better-than-expected second-quarter fiscal 2026 results, with earnings per share of $6.55 topping the consensus estimate of roughly $6.17.
JBDI is a micro-cap container reconditioning company that has pivoted toward technology and hospitality via debt-funded acquisitions, triggering extreme volatility and a sharp speculative rally in recent sessions. VSTM is a clinical-to-commercial oncology company advancing its avutometinib plus defactinib Co-Pack and the experimental drug VS-7375, supported by positive early data and a recent financing.
JBDI is a Singapore-based industrial container reconditioning company that recently announced a $900 million acquisition, driving extreme volatility and a triple-digit single-session surge. NXGL is a U.S.-based hydrogel manufacturer reporting revenue growth but widening net losses and a sharp decline in its share price over the past year.
Different business models: FMFC is a Cambodia-based maker of handbags and leather goods, while JBDI is a Singapore-based industrial container reconditioner pivoting toward AI. Divergent catalysts: JBDI's recent surge was driven by a proposed $900 million acquisition of an AI-powered social platform, whereas FMFC has shown no comparable single transformative event.
BDRX is a clinical-stage biopharmaceutical company, while JBDI operates in the industrial container reconditioning and trading business — two fundamentally different risk profiles. Both stocks are micro-cap and highly volatile, but their recent market behavior has diverged sharply, with JBDI experiencing a sharp short-term price surge while BDRX has trended lower.
GME is trading up +2.06% at $27.78 during Wednesday's regular session, versus Tuesday's close of $27.22. The advance began in after-hours trading Tuesday and carried into the regular session.
CORD is a London-listed investment trust owning digital infrastructure (data centres, fibre networks, and communications towers) across Europe and North America, while JBDI is a Singapore-based supplier of reconditioned and new industrial containers. The two companies occupy fundamentally different markets, sizes, and risk profiles, making this a contrast of stable infrastructure income versus a small-cap, event-driven mover.
JBDI is a Singapore-based container reconditioning and recycling business that recently announced a $900 million, all-notes acquisition of the AI-powered social platform ZYMIX, triggering extreme share-price volatility. NCPL is a Boston-based fintech that operates an online platform for private companies to raise capital and offers advisory services, a structurally different business from JBDI's industrial roots.
JBDI is a Singapore-based industrial container company whose shares recently surged on a proposed $900 million acquisition of an AI-powered social platform, driving extreme volatility. LQDA is a commercial-stage biopharmaceutical company scaling sales of YUTREPIA, its approved therapy for pulmonary hypertension conditions.
Different universes: GENK is a U.S. Korean BBQ restaurant operator, while JBDI is a Singapore-based industrial container reconditioner making a high-profile pivot toward AI. Contrasting momentum: JBDI has surged in recent weeks on a transformative acquisition announcement, while GENK has traded near multi-month lows amid weak same-store sales.
JBDI is a Singapore-based industrial container and recycling business that has pivoted aggressively toward acquisition-driven growth, recently announcing deals far larger than its own market value. TCRT is a pre-clinical stage biopharmaceutical company refocused on oral small-molecule therapies for obesity and metabolic disorders, operating with minimal revenue and a very small market capitalization.